Duality Biotherapeutics, Inc. (SEHK: 9606)
Health Care · Biotechnology · CN
HK$182.70
-6.64% today · -41.3% 1Y
Duality Biotherapeutics, Inc. (SEHK: 9606) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.11B and employs 231 people.
Over the last twelve months the share price has lost 41.3%, trading between 158.50 and 376.80.
Tweenvest scores Duality Biotherapeutics, Inc. across four factors: quality 75/100, value 53/100. Its strongest factor is quality.
9606 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.11B
- Revenue (TTM)
- $123.97M
- P/E
- —
- EPS
- -16.09
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$376.80
- 52-week low
- HK$158.50
- Avg volume (3M)
- —
- Shares outstanding
- 90.54M
- Employees
- 231
- Next earnings
- —
About Duality Biotherapeutics, Inc.
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.
- ISIN
- KYG2929M1087
- Founded
- 2019
- Listed since
- Apr 15, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vera Therapeutics, Inc.NasdaqGM: VERA | $2.15B | $28.17 | -5.72% |
| SK bioscience Co.,Ltd.KOSE: A302440 | $2.13B | ₩36,750.00 | +0.68% |
| Anhui Anke Biotechnology (Group) Co., Ltd.SZSE: 300009 | $2.12B | CN¥8.53 | +1.79% |
| Viridian Therapeutics, Inc.NasdaqCM: VRDN | $2.11B | $18.42 | -1.29% |
| Novavax, Inc.NasdaqGS: NVAX | $2.10B | $12.55 | -1.61% |
| Mineralys Therapeutics, Inc.NasdaqGS: MLYS | $2.07B | $22.31 | -4.54% |
| AlvotechNasdaqGM: ALVO | $2.06B | $5.52 | -4.58% |
| Vericel CorporationNasdaqGM: VCEL | $2.05B | $40.28 | +0.45% |
Figures last refreshed Oct 11, 2026.